323 related articles for article (PubMed ID: 25874287)
1. [Carfilzomib in multiple myeloma relapses].
Bay JO
Bull Cancer; 2015 Feb; 102(2):116. PubMed ID: 25874287
[No Abstract] [Full Text] [Related]
2. A new standard of care in newly diagnosed multiple myeloma.
Richardson PG
Lancet; 2010 Dec; 376(9758):2043-4. PubMed ID: 21146204
[No Abstract] [Full Text] [Related]
3. Multiple myeloma, version 1.2013.
Anderson KC; Alsina M; Bensinger W; Biermann JS; Cohen AD; Devine S; Djulbegovic B; Faber EA; Gasparetto C; Hernandez-Illizaliturri F; Huff CA; Kassim A; Krishnan AY; Liedtke M; Meredith R; Raje N; Schriber J; Singhal S; Somlo G; Stockerl-Goldstein K; Treon SP; Weber D; Yahalom J; Yunus F; Shead DA; Kumar R
J Natl Compr Canc Netw; 2013 Jan; 11(1):11-7. PubMed ID: 23307977
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
5. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
6. "IM iD"eally treating multiple myeloma.
Lacy MQ
Blood; 2013 Mar; 121(11):1926-8. PubMed ID: 23493767
[TBL] [Abstract][Full Text] [Related]
7. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L; Self SE; Velez JC
BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
[TBL] [Abstract][Full Text] [Related]
8. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib plus melphalan and prednisone for multiple myeloma.
Islam A; Ambrus JL
N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19073984
[No Abstract] [Full Text] [Related]
10. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Mele G; Spina A; Guaragna G; Giannotta A; Melpignano A; Quarta G
Leuk Lymphoma; 2014 May; 55(5):1191-3. PubMed ID: 23829305
[No Abstract] [Full Text] [Related]
11. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
12. Controversies regarding the use of dexamethasone in patients with multiple myeloma.
Rajkumar SV
Clin Adv Hematol Oncol; 2008 Feb; 6(2):103, 141. PubMed ID: 18347560
[No Abstract] [Full Text] [Related]
13. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed and refractory myeloma.
Kaufman J; Gleason C; Lonial S
Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Hornberger J; Rickert J; Dhawan R; Liwing J; Aschan J; Löthgren M
Eur J Haematol; 2010 Dec; 85(6):484-91. PubMed ID: 20846301
[TBL] [Abstract][Full Text] [Related]
16. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
Chim CS
Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
[No Abstract] [Full Text] [Related]
17. Treatment options for relapsed and refractory multiple myeloma.
Lonial S; Mitsiades CS; Richardson PG
Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442
[TBL] [Abstract][Full Text] [Related]
18. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
Huang H; Zhou L; Peng L; Fu W; Zhang C; Hou J
Leuk Res; 2014 Sep; 38(9):1048-54. PubMed ID: 25052306
[TBL] [Abstract][Full Text] [Related]
20. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
[No Abstract] [Full Text] [Related]
[Next] [New Search]
